Suppr超能文献

肝切除术治疗有效的化疗时代的晚期或侵袭性结直肠癌肝转移:综述。

Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review.

机构信息

Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.

出版信息

Int J Clin Oncol. 2011 Oct;16(5):452-63. doi: 10.1007/s10147-011-0291-6. Epub 2011 Jul 26.

Abstract

Liver surgery has been known to cure metastatic colorectal cancer in a small proportion of patients. However, advances in procedural technique and chemotherapy now allow more patients to have safe, potentially curative surgery. Here we review surgery for unresectable colorectal liver metastases using an expert multidisciplinary approach. With multidisciplinary management of patients with effective chemotherapy that can downstage metastases, more patients with previously inoperable disease can benefit from surgery. Portal vein embolization results in hypertrophy of the future liver remnant; on occasions, combining embolization with staged liver resection permits potentially curative surgery for patients previously unable to survive resection. However, increasing use of chemotherapy has raised awareness of potential hepatotoxicity and other deleterious effects of cytotoxic agents. Prolonged prehepatectomy chemotherapy therefore can reduce resectability even using a 2-stage procedure. Suitable timing of surgery for unresectable liver metastases during chemotherapy is critical. Because of advances in chemotherapy, colorectal cancer, like ovarian cancer, can now show survival benefit from maximum surgical debulking. Benefit from such maximum hepatic debulking surgery for metastatic colorectal disease is uncertain, but likely. Surgery in isolation may be approaching technical limits, but is now likely to help more patients because of the success of complementary strategies, particularly newer chemotherapy and targeted therapy. Expert individualized multidisciplinary treatment planning and problem-solving is essential.

摘要

肝切除术已被证实能治愈一小部分转移性结直肠癌患者。然而,目前手术技术和化疗的进步使更多的患者能够安全地接受潜在治愈性手术。在这里,我们采用多学科专家团队的方法,综述不可切除的结直肠肝转移瘤的手术治疗。通过多学科管理和有效的化疗使转移灶降期,更多原本无法手术的患者可以从手术中获益。门静脉栓塞可导致未来肝脏残块的肥大;在某些情况下,联合栓塞和分期肝切除可以使以前无法切除的患者获得潜在治愈性手术。然而,化疗的广泛应用使人们意识到细胞毒性药物潜在的肝毒性和其他有害作用。因此,即使采用两阶段手术,长时间的术前化疗也可能降低可切除性。在化疗过程中,对不可切除的肝转移灶进行手术的适当时机至关重要。由于化疗的进步,结直肠癌与卵巢癌一样,现在可以从最大程度的手术减瘤中获得生存获益。转移性结直肠疾病是否能从这种最大程度的肝减瘤手术中获益尚不确定,但很可能获益。单独手术可能已接近技术极限,但由于补充策略(尤其是新型化疗和靶向治疗)的成功,现在可能会帮助更多的患者。个体化的多学科专家治疗计划和问题解决至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验